Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells

BACKGROUND: Standard-of-care therapies for treating pediatric medulloblastoma have long-term side effects, even in children who are cured. One emerging modality of cancer therapy that could be equally effective without such side effects would be chimeric antigen receptor (CAR) T cells. Knowing that...

Descripción completa

Detalles Bibliográficos
Autores principales: Nellan, Anandani, Rota, Christopher, Majzner, Robbie, Lester-McCully, Cynthia M., Griesinger, Andrea M., Mulcahy Levy, Jean M., Foreman, Nicholas K., Warren, Katherine E., Lee, Daniel W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925833/
https://www.ncbi.nlm.nih.gov/pubmed/29712574
http://dx.doi.org/10.1186/s40425-018-0340-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925833/
https://www.ncbi.nlm.nih.gov/pubmed/29712574
http://dx.doi.org/10.1186/s40425-018-0340-z

Ejemplares similares